Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 2/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.40 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.39 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | PIK3C3 | Q8NEB9 | 10/20 | 0.38 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.36 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.36 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.36 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19133730 | 0.87 | ACACB (0.43) | ACACBTGFBR1TGFBR2AAK1CYP3A4 | |
| SCHEMBL17863762 | 0.85 | GRM5 (0.50) | TGFBR1TGFBR2PIK3C3 | |
| SCHEMBL25231512 | 0.84 | JAK2 (0.41) | AAK1PIK3C3 | |
| SCHEMBL30365668 | 0.84 | JAK2 (0.41) | AAK1PIK3C3 | |
| SCHEMBL17840543 | 0.84 | GRM5 (0.41) | TGFBR1TGFBR2CYP3A4PIK3C3 | |
| SCHEMBL17840686 | 0.81 | ACACB (0.38) | ACACBTGFBR1TGFBR2FFAR1CYP1A2 | |
| SCHEMBL17840896 | 0.80 | AAK1 (0.43) | ACACBMAPK8MAPK9AAK1CYP3A4 | |
| SCHEMBL17840742 | 0.80 | JAK2 (0.41) | AAK1PIK3C3 | |
| SCHEMBL17840730 | 0.80 | MET (0.42) | MAPK8MAPK9TGFBR1AAK1CYP3A4 | |
| SCHEMBL17840536 | 0.77 | PIK3C3 (0.44) | AAK1PIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3237415-A1 | TGF RECEPTOR ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2017-11-01 | — | — | EP | disclosed |
| US-9708316-B2 | TGFβR antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708316-B2 | TGFβR antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-18 | — | — | US | disclosed |
| WO-2016106266-A1 | TGFβ RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016106266-A1 | TGFβ RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-06-30 | — | — | WO | disclosed |
| US-20160176871-A1 | TGF BETA R ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2016-06-23 | — | — | US | disclosed |
| US-20160176871-A1 | TGF BETA R ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176871-A1 | TGF BETA R ANTAGONISTS | TGFBR2, TGFBR1, TGFB1 | ACACB 2045/4885MAPK8 1690/4885MAPK9 1406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.